Copenhagen, Denmark

Elsebet Østergaard Nielsen

This inventor holds 65 USPTO granted patents and 46 published patent applications, primarily in Neurotransmitter Modulators (CPC class C07D). Top assignees: Neurosearch A/s, Aniona Aps, Danpet Ab. Active years: 2005-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elsebet Østergaard Nielsen. Retrieved from https://idiyas.com/inventor/elsebet-østergaard-nielsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 65 

% Patents Active = 20.0

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 108(Granted Patents)

Forward Citations (Not Self Cited) = 90(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Kobenhavn K, DK (2006)
  • Kobenhavn, DE (2007)
  • Kobenhavn K., DK (2007)
  • Købenkavn K, DK (2010)
  • Ballerup, DK (2007 - 2012)
  • København, DK (2005 - 2014)
  • København K, SE (2014)
  • København K, DK (2005 - 2015)
  • Copenhagen, DK (2010 - 2015)

Company Filing History:


Years Active: 2005-2015

Loading Chart...
Areas of Expertise:
Nicotinic Acetylcholine Receptor
Monoamine Neurotransmitter
Oxadiazolyl Compounds
Diazabicyclononane
Chromen Derivatives
Piperidine Derivatives
Anxiety Treatment
Pharmaceutical Use
Medical Applications
Copenhagen, DK
65 patents (USPTO):Explore Patents

Article: Elsebet Østergaard Nielsen: Pioneering Innovator in the Field of Medical Inventions

Introduction:

Elsebet Østergaard Nielsen, a visionary inventor hailing from København K, Denmark, has made significant strides in the realm of medical innovations. With an impressive portfolio of 65 patents to his name, Nielsen's groundbreaking work has revolutionized the field of pharmaceuticals and neuroimaging.

Latest Patents:

Among his latest patents are the "Labelled and un-labelled methyl-pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use." This invention focuses on the use of certain derivatives in diagnostic methods, particularly in neuroimaging. Additionally, Nielsen's "Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators" showcases his expertise in developing compounds for the treatment of a wide range of diseases related to the central and peripheral nervous systems.

Career Highlights:

Nielsen's illustrious career includes tenures at renowned companies such as Neurosearch A/S and Aniona ApS. His relentless pursuit of innovation and commitment to creating sustainable solutions have cemented his reputation as a trailblazer in the field of medical inventions. Nielsen's work has not only advanced the field of pharmaceuticals but has also contributed significantly to enhancing patient care and treatment outcomes.

Collaborations:

Throughout his career, Nielsen has collaborated with esteemed professionals in the industry, including Dan Peters and Gunnar M. Olsen. These collaborations have led to the development of groundbreaking inventions and propelled Nielsen's work to new heights. By fostering a culture of teamwork and cooperation, Nielsen has been able to bring his visionary ideas to fruition and make a lasting impact on the field of medical inventions.

Conclusion:

Elsebet Østergaard Nielsen's innovative spirit and dedication to creating a sustainable future through his inventions have solidified his position as a true visionary in the world of medical innovations. His unwavering commitment to pushing the boundaries of what is possible in pharmaceuticals and neuroimaging serves as an inspiration to aspiring inventors and researchers worldwide. Nielsen's contributions to the field will undoubtedly continue to shape the landscape of medical inventions for years to come, leaving a lasting legacy in the pursuit of improved patient care and innovative treatment solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…